Pure Global AI
NCT06295432Recruiting

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

A Phase II, Multicenter Study to Assess the Safety, Tolerability and Anti-tumor Efficacy of DZD9008 in Combination With AZD4205 in Standard Treatment Failed Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations
Dizal PharmaceuticalsPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
DZD9008+AZD4205
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Dizal Pharmaceuticals
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2023
End date
Jun 01, 2025
Enrollment
90 participants
Primary outcome

Part A: incidence of DLT , ≥grade 3 TEAEs and SAEs; Part B: incidence of ≥grade 3 TEAEs as assessed by CTCAE, incidence of SAEs.

Summary

DZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with
 EGFR mutations who have progressed after standard treatment. The purpose of this study is to
 assess the safety and efficacy of this combination therapy.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06295432
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06295432 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dizal Pharmaceuticals and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.